Biotech · Private company · Radnor, PA, US
Marinus Pharmaceuticals, Inc.
SEC CIK 0001267813
Track this companyFree. Adds Marinus Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials190 recruiting or active
Pipeline programs16From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline16
- ganaxolonePhase 3 · Drug Resistant Partial Onset SeizureClinicalTrials.gov · fetched Nov 12, 2026
- ganaxolonePhase 3 · CDKL5 Deficiency DisorderClinicalTrials.gov · fetched Nov 12, 2026
- GanaxolonePhase 3 · Status EpilepticusClinicalTrials.gov · fetched Nov 12, 2026
- GanaxolonePhase 3 · Tuberous Sclerosis ComplexClinicalTrials.gov · fetched Nov 12, 2026
- ganaxolonePhase 2 · Epilepsy, Complex PartialClinicalTrials.gov · fetched Nov 12, 2026
- ganaxolonePhase 2 · Epilepsies, PartialClinicalTrials.gov · fetched Nov 12, 2026
- GanaxolonePhase 2 · PCDH19-Related EpilepsyClinicalTrials.gov · fetched Nov 12, 2026
- GanaxolonePhase 2 · PTSDClinicalTrials.gov · fetched Nov 12, 2026
- GanaxolonePhase 2 · Tuberous SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- GanaxolonePhase 2 · Infantile SpasmsClinicalTrials.gov · fetched Nov 12, 2026
- GanaxolonePhase 2 · DepressionClinicalTrials.gov · fetched Nov 12, 2026
- GanaxolonePhase 2 · Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- GanaxolonePhase 2 · EpilepsyClinicalTrials.gov · fetched Nov 12, 2026
- GanaxolonePhase 2 · Fragile x SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- GanaxolonePhase 2 · Partial EpilepsyClinicalTrials.gov · fetched Nov 12, 2026
- IV Ganaxolone activePhase 2 · Status EpilepticusClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials19
- Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related EpilepsyPHASE3 · TERMINATED · started May 16, 2022ClinicalTrials.gov NCT05604170 · fetched Nov 12, 2026
- Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related EpilepsyPHASE3 · COMPLETED · started Apr 1, 2022ClinicalTrials.gov NCT05323734 · fetched Nov 12, 2026
- Randomized Therapy In Status EpilepticusPHASE3 · COMPLETED · started Dec 9, 2020ClinicalTrials.gov NCT04391569 · fetched Nov 12, 2026
- Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)PHASE2 · COMPLETED · started Apr 8, 2020ClinicalTrials.gov NCT04285346 · fetched Nov 12, 2026
- Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)PHASE2 · COMPLETED · started May 17, 2019ClinicalTrials.gov NCT03865732 · fetched Nov 12, 2026
- Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency DisorderPHASE3 · COMPLETED · started Jun 30, 2018ClinicalTrials.gov NCT03572933 · fetched Nov 12, 2026
- Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status EpilepticusPHASE2 · COMPLETED · started Feb 19, 2018ClinicalTrials.gov NCT03350035 · fetched Nov 12, 2026
- A Clinical Trial of Oral Ganaxolone in Women With Postpartum DepressionPHASE2 · COMPLETED · started Dec 28, 2017ClinicalTrials.gov NCT03460756 · fetched Nov 12, 2026
- A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum DepressionPHASE2 · COMPLETED · started Jun 27, 2017ClinicalTrials.gov NCT03228394 · fetched Nov 12, 2026
- Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic EpilepsiesPHASE2 · COMPLETED · started Nov 6, 2015ClinicalTrials.gov NCT02358538 · fetched Nov 12, 2026
- A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset SeizuresPHASE3 · TERMINATED · started Feb 1, 2015ClinicalTrials.gov NCT02519439 · fetched Nov 12, 2026
- Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label ExtensionPHASE3 · COMPLETED · started Oct 1, 2013ClinicalTrials.gov NCT01963208 · fetched Nov 12, 2026
- Ganaxolone Treatment in Children With Fragile X SyndromePHASE2 · COMPLETED · started Nov 1, 2012ClinicalTrials.gov NCT01725152 · fetched Nov 12, 2026
- Ganaxolone in Posttraumatic Stress Disorder (PTSD)PHASE2 · COMPLETED · started Apr 1, 2011ClinicalTrials.gov NCT01339689 · fetched Nov 12, 2026
- A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601PHASE2 · COMPLETED · started Oct 1, 2009ClinicalTrials.gov NCT01002820 · fetched Nov 12, 2026
- Open-label Extension to Protocol 1042-0600PHASE2 · COMPLETED · started Jun 1, 2007ClinicalTrials.gov NCT00512317 · fetched Nov 12, 2026
- A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset SeizuresPHASE2 · COMPLETED · started Feb 1, 2007ClinicalTrials.gov NCT00465517 · fetched Nov 12, 2026
- A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile SpasmsPHASE2 · COMPLETED · started Jan 1, 2007ClinicalTrials.gov NCT00441896 · fetched Nov 12, 2026
- Open-label Extension to Protocol 1042-0500PHASE2 · TERMINATED · started Jan 1, 2007ClinicalTrials.gov NCT00442104 · fetched Nov 12, 2026
SEC filings6
- 8-K · FORM 8-KSEC EDGAR · filed Feb 11, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Dec 30, 2024 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Dec 30, 2024 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 23, 2024 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 10, 2024 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 15, 2024 · fetched Nov 12, 2026